Virtual Trials Market To Raise At A CAGR Of 6.7% From 2022 To 2027

The market for virtual trials was valued at $8.2 billion in 2021; from 2022 to 2027, it is anticipated to increase at a compound annual growth rate (CAGR) of 6.7%.

Telemedicine is the foundation of virtual trials, which use specialized apps for patient participation and tracking. They significantly lessen the time and budgetary costs. Patients can enroll in virtual trials from their homes and be monitored remotely. Furthermore, rather than relying on a single location for treatments, virtual trials give patients access to a variety of physicians throughout the nation or the world for more specialized care. It might lessen patient dropout and shorten trial timelines, two of the most important difficulties in life sciences research and development. Additionally, the adoption of AI technology helps hasten the process of synthesizing and analyzing ever-growing data. Clinical trial sponsors and life science companies are becoming more and more interested in virtual trials due to these advantages.

Companies were obliged to switch to virtual studies when the Covid-19 outbreak placed many clinical trials on hold to resume research. Startups offering services for decentralized clinical trials now have a chance as a result. Since then, there have been more venture capital funding transactions. In 2018, there were six deals; in 2020, there will be 18 deals. In Q3 2020, VC funding was most prevalent (10 deals). Notably, since 2020, Medable, one of the companies offering decentralized trial platforms with the quickest growth, has raised $524 million through multiple stages. In one of the largest rounds, the business got a massive $304 million Series D fundraising in October 2021. Companies will be able to develop new technologies and expand their customer and geographic reach as VC funding increases. This will lead to a rise in market adoption generally.

A virtual approach enables participants to take part in the assessment from the comfort of their own homes, ensuring that research can continue even in the absence of site visits and addressing a clever method of acquiring health and viability data from participants in clinical examinations. Members have a choice and genuine peace of mind knowing they won't be exposed to unnecessary risks thanks to virtual visits and remote patient observation of in-person site visits. The use of virtual exams allows supporters to recall a larger population for the test, so boosting enrolment, commitment, and maintenance. Additionally, it facilitates continuous information gathering through computerized health advancements. Finally, a virtual network that includes executives, as well as observers, can completely reduce the workload, time commitment, and burden on members, CRCs, and examiners.

Key Market Insights:

  • With a 46.7% revenue share in 2021, the interventional design segment dominated the Virtual/Decentralized Clinical Trials (DCTs) market. The industry is being driven by the quick growth in studies to create new drugs for different diseases as well as the digitalization of laboratories. The coronavirus outbreak has increased the need for research and trials of novel medications and vaccines to address the issue globally because the standard approach of clinical trials carries a significant risk of human infection. Consequently, the need for interventional study designs is increasing.
  • With a 25.2% revenue share in 2021, the oncology segment topped the market for virtual/decentralized clinical trials. During the projected period, the sector is also anticipated to contribute the greatest market share. This is due to both the increased number of oncology clinical trials and the rising number of cancer cases worldwide. The COVID-19 pandemic is most dangerous to cancer patients. To keep patients safe and clinical trials going forward, investigators and sponsors handling oncology clinical trials have quickly adopted virtual and remote trials.
  • With a revenue share of 49.2% in 2021, North America dominated the market for virtual trials. Over the forecast period, the category is anticipated to keep leading. This is due to increased government assistance, increased acceptance of new technology in clinical research, and increased R&D in this area. Market participants are also utilizing digital technologies to satisfy customer needs. Parexel, for example, conducted more than 100 decentralized trials using hybrid and virtual techniques. Along with providing the trial to patients, Covance also operates about 1,900 LabCorp Patient Service Centers across the United States.
  • The region in Asia Pacific is anticipated to experience the greatest CAGR over the projected period, which can be attributed to the region's growing accessibility to a sizable patient pool that facilitates easy recruitment of rivals and increased entry of technological advancements. Additionally, the resurgence of Covid is anticipated to enhance the acceptance of telemedicine, driving the industry in the area. Due in large part to its high medical care, R&D, and interest in virtual trials, Japan was the largest market in the Asia Pacific region in 2021.

Market Segmentation:

By Study Design

  • Interventional
  • Observational
  • Expanded Access

By Indication

  • Oncology
  • Cardiovascular
  • CNS
  • Autoimmune/Inflammation
  • Metabolic/Endocrinology
  • Infectious Disease
  • Genitourinary
  • Ophthalmology
  • Others

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Analyst Support

Every order comes with Analyst Support

Customization

We offer customization to cater your needs to fullest

Verified Analysis

We value Integrity, quality and authenticity the most